Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brostallicin in Advanced Soft Tissue Sarcoma
NCT00041249Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- May 2002
- Primary completion
- Jan 2004
- Modality
- DNA Intercalators/Alkylators, Recombinant Proteins and Enzymes, Prodrugs/Conditional Activator Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label trial of brostallicin in soft tissue sarcoma (STS) and gastrointestinal stromal tumor (GIST) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Objective Response. Started May 2002; status: completed.
02
Drugs
brostallicin
03
Conditions
soft tissue sarcoma (STS)gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT00041249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00041249.